JP2011515078A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515078A5
JP2011515078A5 JP2010549777A JP2010549777A JP2011515078A5 JP 2011515078 A5 JP2011515078 A5 JP 2011515078A5 JP 2010549777 A JP2010549777 A JP 2010549777A JP 2010549777 A JP2010549777 A JP 2010549777A JP 2011515078 A5 JP2011515078 A5 JP 2011515078A5
Authority
JP
Japan
Prior art keywords
composition
cancer
mirna
nucleic acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515078A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/035660 external-priority patent/WO2009111375A2/en
Publication of JP2011515078A publication Critical patent/JP2011515078A/ja
Publication of JP2011515078A5 publication Critical patent/JP2011515078A5/ja
Pending legal-status Critical Current

Links

JP2010549777A 2008-03-01 2009-03-02 ＳＰＡＲＣ特異的ｍｉＲＮＡを使用する、治療、診断、及び拮抗物質発見方法 Pending JP2011515078A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3296108P 2008-03-01 2008-03-01
US61/032,961 2008-03-01
PCT/US2009/035660 WO2009111375A2 (en) 2008-03-01 2009-03-02 Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas

Publications (2)

Publication Number Publication Date
JP2011515078A JP2011515078A (ja) 2011-05-19
JP2011515078A5 true JP2011515078A5 (https=) 2011-09-22

Family

ID=40707714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549777A Pending JP2011515078A (ja) 2008-03-01 2009-03-02 ＳＰＡＲＣ特異的ｍｉＲＮＡを使用する、治療、診断、及び拮抗物質発見方法

Country Status (6)

Country Link
US (1) US20090220589A1 (https=)
EP (1) EP2257626A2 (https=)
JP (1) JP2011515078A (https=)
AU (1) AU2009222056A1 (https=)
CA (1) CA2717169A1 (https=)
WO (1) WO2009111375A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2390425T3 (es) * 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
EP2487258B1 (en) 2006-01-05 2014-10-01 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
AU2008283795B2 (en) 2007-07-31 2013-11-21 Board Of Regents, The University Of Texas System A micro-RNA family that modulates fibrosis and uses thereof
JP2010535473A (ja) 2007-08-03 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン ｎｃＲＮＡをコードする超保存領域
WO2009108853A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CA2718520C (en) 2008-03-17 2020-01-07 The Board Of Regents Of The University Of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
WO2011043739A1 (en) * 2009-10-09 2011-04-14 Singapore Health Services Pte. Ltd. Methods and compositions for maintenance of a functional wound
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
CN102656190A (zh) 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
US20130131148A1 (en) * 2010-04-12 2013-05-23 Noam Shomron Micro-rna for cancer diagnosis, prognosis and therapy
WO2011130464A1 (en) * 2010-04-14 2011-10-20 Abraxis Bioscience, Llc Translational regulation of sparc by the micrornas mir29a, b and c
US20130139273A1 (en) * 2010-06-24 2013-05-30 The Ohio State University Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted miR-29 Expression
WO2012006181A2 (en) * 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
CN102382823B (zh) * 2010-09-01 2013-04-24 中国科学院上海药物研究所 人miR-515-5p反义核酸及其应用
JP5931897B2 (ja) 2010-11-12 2016-06-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
WO2012093384A1 (en) * 2011-01-03 2012-07-12 Rosetta Genomics Ltd. Compositions and methods for treatment of ovarian cancer
TWI421084B (zh) * 2011-04-01 2014-01-01 Univ Kaohsiung Medical 微小ＲＮＡ ｌｅｔ－７ｇ的新用途
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
NZ714482A (en) 2012-01-27 2017-08-25 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
JP6129544B2 (ja) * 2012-12-18 2017-05-17 花王株式会社 Ｓｐａｒｃ産生促進剤
JP6571663B2 (ja) * 2013-09-14 2019-09-04 ケムジーンズ コーポレーション 逆方向アプローチを使用した長いｒｎａの非常に効果的な合成
WO2017062659A1 (en) * 2015-10-06 2017-04-13 University Of Virginia Patent Foundation Compositions and methods for treating diabetic retinopathy
CN107858416B (zh) * 2016-09-19 2021-05-28 深圳华大生命科学研究院 用于子宫内膜异位症检测的生物标志物组合及其应用
EP3820483A4 (en) * 2018-07-13 2023-03-01 Yale University COMPOSITIONS AND METHODS FOR THE TREATMENT OF ENDOMETRIOSIS

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3852253A (en) * 1972-12-22 1974-12-03 Exxon Research Engineering Co Heterogeneous process for preparing conjugated diene butyl
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) * 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4667013A (en) * 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
ATE269870T1 (de) * 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
ATE174058T1 (de) * 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5223618A (en) * 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5623070A (en) * 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
BR9106702A (pt) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
JPH04167172A (ja) * 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5489743A (en) * 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5858988A (en) * 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5705629A (en) * 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6919208B2 (en) * 2000-05-22 2005-07-19 The Children's Hospital Of Philadelphia Methods and compositions for enhancing the delivery of a nucleic acid to a cell
EP2295604B1 (en) * 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
US7332568B2 (en) * 2005-02-18 2008-02-19 Abraxis Bioscience, Inc. Q3 SPARC deletion mutant and uses thereof
CA2657030A1 (en) * 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
US8466117B2 (en) * 2006-07-28 2013-06-18 The Johns Hopkins University Compositions and methods for modulating angiogenesis

Similar Documents

Publication Publication Date Title
JP2011515078A5 (https=)
US10767178B2 (en) Compositions and methods of using piRNAS in cancer diagnostics and therapeutics
CA2917320C (en) Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, composition containing same for preventing or treating respiratory disease
ES3041629T3 (en) Method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5
KR20120048613A (ko) Ｓｐａｒｃ 안티센스 조성물과 이들의 용도
TW200927176A (en) RNA antagonist compounds for the modulation of PIK3CA expression
JP2014533681A (ja) 神経膠腫を治療するための組成物および方法
CN113667748A (zh) circIKBKB的抑制剂及其检测试剂在乳腺癌骨转移诊断、治疗和预后试剂盒的应用
US20140024702A1 (en) Cancer gene therapy using nucleic acids encoding us28 and g-protein
TW201016222A (en) RNA antagonists targeting GLI2
US11576873B2 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
CN105462975A (zh) 一种特异性抑制ctgf基因表达的小干扰rna及其应用
CN110201172B (zh) Yy1表达抑制剂在制备治疗乳腺癌药物中的应用
CN109477110B (zh) 抑制mex3b基因的表达的核酸、试剂、及疾病的预防或治疗剂
US20140371300A1 (en) Pharmaceutical composition for treating cancer
WO2015042720A1 (en) Novel lincrna and interfering nucleic acid molecules, compositions and methods and uses thereof for regulating angiogenesis and related conditions
KR101286053B1 (ko) ＴＧＦ－β１ 발현을 억제하는 ｓｈＲＮＡ
CN117660447A (zh) 一种促进pdcd1外显子3跳跃的反义寡核苷酸及其应用
CN115529818B (zh) 一种癌的预防或治疗剂、组合医药、以及筛选方法
CN101914536B (zh) 靶向丝-苏氨酸蛋白激酶极光激酶a的锁核酸核酶与应用
EP1574574A1 (en) Exon 1-beta of pdgf receptor alpha gene and utilization thereof
WO2006016574A1 (ja) ＲＮＡｉを利用した抗腫瘍剤
US20100291036A1 (en) Compositions and methods for modulating vascular endothelial growth factor c (vegf-c) expression
JP6934235B2 (ja) 遺伝子発現制御のための発現制御核酸分子およびその用途
WO2026080581A1 (en) Antitumor reagents for increasing sensitivity of malignant tumor cells to chemotherapy and immunotherapy